Literature DB >> 25540303

Acute idiopathic transverse myelitis in children: early predictors of relapse and disability.

Kumaran Deiva1, Michael Absoud2, Cheryl Hemingway2, Yaiza Hernandez2, Béatrice Hussson2, Hélène Maurey2, Giorgios Niotakis2, Evangeline Wassmer2, Ming Lim2, Marc Tardieu2.   

Abstract

OBJECTIVE: To identify early prognostic factors of relapse and disability in children presenting with an acute idiopathic transverse myelitis (TM).
METHODS: Ninety-five children with acute idiopathic TM from 2 national European cohorts (France and United Kingdom) of CNS demyelinating diseases in children were identified and studied for early factors that predict relapse and disability using logistic regression models.
RESULTS: Sixteen (17%) relapsed, with a diagnosis of multiple sclerosis in 13 (14%) and neuromyelitis optica in 3 (3%). Logistic regression revealed 2 main criteria as risk factors for relapse: female sex (odds ratio [OR] 3.21, 95% confidence interval [CI] 0.88-11.78) and presence of associated brain lesions (OR 14.0, 95% CI 2.8-69.3). Twenty-eight (30%) children had a poor outcome defined by a Kurtzke Expanded Disability Status Scale score ≥4 or an American Spinal Injury Association impairment (ASIA) scale <D at last follow-up. Five factors were associated with poor outcome: female sex (OR 5.8, 95% CI 0.99-32.7), severe ASIA scale at onset (OR 33.5, 95% CI 1.8-618), gadolinium enhancement on spinal MRI (OR 24.1, 95% CI 3.78-153.88), absence of pleocytosis (OR 4.6, 95% CI 0.87-26.0), and absence of cervical or cervico-thoracic lesion on spinal MRI (OR 3.9, 95% CI 0.78-19.6).
CONCLUSIONS: Early predictors of relapse and disability identified in this large childhood study of acute idiopathic TM have important utility for clinical management. Larger prospective collaborative studies are required to validate these findings, which may improve the design of clinical trials.
© 2014 American Academy of Neurology.

Entities:  

Mesh:

Year:  2014        PMID: 25540303     DOI: 10.1212/WNL.0000000000001179

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  14 in total

1.  Disease Course and Treatment Responses in Children With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

Authors:  Yael Hacohen; Yu Yi Wong; Christian Lechner; Maciej Jurynczyk; Sukhvir Wright; Bahadir Konuskan; Judith Kalser; Anne Lise Poulat; Helene Maurey; Esther Ganelin-Cohen; Evangeline Wassmer; Chery Hemingway; Rob Forsyth; Eva Maria Hennes; M Isabel Leite; Olga Ciccarelli; Banu Anlar; Rogier Hintzen; Romain Marignier; Jacqueline Palace; Matthias Baumann; Kevin Rostásy; Rinze Neuteboom; Kumaran Deiva; Ming Lim
Journal:  JAMA Neurol       Date:  2018-04-01       Impact factor: 18.302

2.  Transverse Myelitis in a Child with Chronic Recurrent Multifocal Osteomyelitis.

Authors:  Natan Cramer
Journal:  Neurohospitalist       Date:  2022-04-23

Review 3.  Pediatric Acquired Demyelinating Disorders.

Authors:  J Nicholas Brenton
Journal:  Continuum (Minneap Minn)       Date:  2022-08-01

4.  Gait Characteristics in Youth With Transverse Myelitis.

Authors:  Miriam Hwang; Ann Flanagan; Adam Graf; Karen M Kruger; Nancy Scullion; Samantha Tayne; Haluk Altiok
Journal:  Top Spinal Cord Inj Rehabil       Date:  2021-08-13

5.  Diagnostic transcranial magnetic stimulation as a prognostic tool in children with acute transverse myelitis.

Authors:  V B Voitenkov; A V Klimkin; N V Skripchenko; N F Pulman; M V Ivanova
Journal:  Spinal Cord       Date:  2015-08-04       Impact factor: 2.772

Review 6.  Pain and spinal cord imaging measures in children with demyelinating disease.

Authors:  Nadia Barakat; Mark P Gorman; Leslie Benson; Lino Becerra; David Borsook
Journal:  Neuroimage Clin       Date:  2015-09-06       Impact factor: 4.881

Review 7.  Magnetic Resonance Imaging and Clinical Features in Acute and Subacute Myelopathies.

Authors:  Stefan Weidauer; Marlies Wagner; Michael Nichtweiß
Journal:  Clin Neuroradiol       Date:  2017-06-30       Impact factor: 3.156

8.  Protocol for a multicentre randomiSed controlled TRial of IntraVEnous immunoglobulin versus standard therapy for the treatment of transverse myelitis in adults and children (STRIVE).

Authors:  M Absoud; J Gadian; J Hellier; P A Brex; O Ciccarelli; G Giovannoni; J Kelly; P McCrone; C Murphy; J Palace; A Pickles; M Pike; N Robertson; A Jacob; M Lim
Journal:  BMJ Open       Date:  2015-05-25       Impact factor: 2.692

9.  Safety and efficacy of plasma exchange in pediatric transverse myelitis.

Authors:  Daniel K Noland; Benjamin M Greenberg
Journal:  Neurol Clin Pract       Date:  2018-08

10.  Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients.

Authors:  Daniel H Whittam; Alvaro Cobo-Calvo; A Sebastian Lopez-Chiriboga; Santiago Pardo; Matthew Gornall; Silvia Cicconi; Alexander Brandt; Klaus Berek; Thomas Berger; Ilijas Jelcic; Grace Gombolay; Luana Micheli Oliveira; Dagoberto Callegaro; Kimihiko Kaneko; Tatsuro Misu; Marco Capobianco; Emily Gibbons; Venkatraman Karthikeayan; Bruno Brochet; Bertrand Audoin; Guillaume Mathey; David Laplaud; Eric Thouvenot; Mikaël Cohen; Ayman Tourbah; Elisabeth Maillart; Jonathan Ciron; Romain Deschamps; Damien Biotti; Kevin Rostasy; Rinze Neuteboom; Cheryl Hemingway; Rob Forsyth; Marcelo Matiello; Stewart Webb; David Hunt; Katy Murray; Yael Hacohen; Ming Lim; M Isabel Leite; Jacqueline Palace; Tom Solomon; Andreas Lutterotti; Kazuo Fujihara; Ichiro Nakashima; Jeffrey L Bennett; Lekha Pandit; Tanuja Chitnis; Brian G Weinshenker; Brigitte Wildemann; Douglas Kazutoshi Sato; Su-Hyun Kim; Saif Huda; Ho Jin Kim; Markus Reindl; Michael Levy; Sven Jarius; Silvia Tenembaum; Friedemann Paul; Sean Pittock; Romain Marignier; Anu Jacob
Journal:  Mult Scler Relat Disord       Date:  2020-06-02       Impact factor: 4.339

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.